Case Report

Non-Requirement to Blood Transfusion in a Patent With Myelodysplastc Syndrome Following the Oral Administraton of β-D-Mannuronic Acid: A Case Report

Abstract

Myelodysplastic Syndromes (MDSs) is a heterogeneous group of hematologic neoplasms that causes cytopenia and dysplasia in one or more major bone marrow cell lines. The patients with this syndrome develop clinical complications associated with progressive bone marrow destruction leading to an increased risk for acute myelogenous leukemia. In the treatment of this syndrome, repeated infusion of Red Blood Cells (RBCs) may lead to iron overload, which is associated with a reduction in the survival rate of patients. In this paper, we report a case with MDS whose risk of dependence on blood transfusion was interstitial and received 4 units of packed RBCs once every 4 weeks. He had enrolled in our current clinical trial of β-D-mannuronic acid (M2000) in Iranian MDS patients. This 68-year-old man was treated with M2000, 500-mg capsule every 12 hours for 3 months. After 3 months of treatment, he experienced a non-requirement to blood transfusion following a hemoglobin increase of more than 2.5 g/dL in his blood sample. Moreover, the patient’s life quality was improved. This case report showed that M2000 drug might be an effective treatment for transfusion- dependent MDS patients (Clinical trial identifier; IRCT20130622013739N11).

[1] Pirayesh A, Verbunt R, Kluin PM, Meinders A, De Meijer P. Myelodysplastc syndrome with vasculitc manifestatons. Journal of Internal Medicine. 1997; 242(5):425-31. [DOI:10.1046/j.1365- 2796.1997.00213.x] [PMID]
[2] Tefferi A, Vardiman JW. Myelodysplastc syndromes. New England Journal of Medicine. 2009; 361(19):1872-85. [DOI:10.1056/NEJMra0902908] [PMID]
[3] Ma X. Epidemiology of myelodysplastc syndromes. American Journal of Medicine. 2012; 125(7):S2-5. [DOI:10.1016/j.amjmed.2012.04.014] [PMID] [PMCID]
[4] Germing U, Kündgen A. Prognostc scoring systems in MDS. Leukemia Research. 2012; 36(12):1463-9. [DOI:10.1016/j.leukres.2012.08.005] [PMID]
[5] Fatahi MJ, Abdollahi M, Agha Mohammadi A, Rastkari N, Khorasani R, Ahmadi H, et al. Preclinical assessment of β-d mannuronic acid (M2000) as a non-steroidal ant-inflammatory drug. Immunopharmacology and Immunotoxicology. 2015; 37(6):535-40. [DOI:10. 3109/08923973.2015.1113296] [PMID]
[6] Mirshafey A, Taeb M, Mortazavi-Jahromi S, Jafarnezhad-Ansariha F, Rehm BH, Esposito E, et al. Introducton of β-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1/ COX-2 actvity and gene expression. Pharmacological Reports. 2017;
69(5):1067-72. [DOI:10.1016/j.pharep.2017.04.015] [PMID]
[7] Fatahi MJ, Jamshidi AR, Mahmoudi M, Vojdanian M, Yekaninejad MS, Jafarnezhad-Ansariha F, et al. Evaluaton of the efcacy and safety of β-d-mannuronic acid in patents with ankylosing spondylits: A 12-week randomized, placebo-controlled, phase I/II clinical trial. Internatonal Immunopharmacology. 2018; 54:112-7. [DOI:10.1016/j.intmp.2017.11.003] [PMID]
[8] Ahmadi H, Jamshidi AR, Mahmoudi M, Gharibdoost F, Vojdanian M, Fatahi MJ, et al. Hematological improvement of patents with actve rheumatoid arthrits by β-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property. Iranian Journal of Allergy, Asthma and Immunology. 2017; 16(5):433-42.
[9] Farahani MM, Motevaseli E, Maghsood F, Heidari-Kharaji M, Mirshafey A. Ant-inflammatory property of β-D mannuronic acid (M2000) on expression and actvity of matrix metalloproteinase-2 and-9 through CD147 molecule in phorbol myristate acetate-differentated THP-1 cells. Iranian Journal of Allergy, Asthma and Immunology. 2017; 16(5):443-51.
[10] Hosseini F, Hassannia H, Mahdian-Shakib A, Jadidi-Niaragh F, Enderami SE, Fatahi M, et al. Targetng of crosstalk between tumor and tumor microenvironment by β-D mannuronic acid (M2000) in murine breast cancer model. Cancer Medicine. 2017; 6(3):640-50. [DOI:10.1002/cam4.1013] [PMID] [PMCID]
[11] Rastegari-Pouyani M, Mostafaie A, Mansouri K, Mortazavi-Jahromi SS, Mohammadi-Motlagh HR, Mirshafey A. Ant angiogenesis effect of β-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive propertes under experimental model. Clinical and Experimental Pharmacology and Physiology. 2018; 45(4):370-6. [DOI:10.1111/1440-1681.12907] [PMID]
[12] Cheson BD, Greenberg PL, Bennet JM, Lowenberg B, Wijermans PW, Nimer SD, et al. Clinical applicaton and proposal for modifcaton of the Internatonal Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108(2):419-25. [DOI:10.1182/ blood-2005-10-4149] [PMID]
Files
IssueVol 4 No 2 (2019): Spring QRcode
SectionCase Report(s)
DOI https://doi.org/10.18502/crcp.v4i2.1708
Keywords
D-mannuronic acid (M2000); Myelodysplastc syndrome (MDS); Transfusion; Hematology; Oncology
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Ghaderi A, Safaee Nodehi SR, Bakhtiari T, Mirshafiey A. Non-Requirement to Blood Transfusion in a Patent With Myelodysplastc Syndrome Following the Oral Administraton of β-D-Mannuronic Acid: A Case Report. CRCP. 2019;4(2):57-60.